Compare UNIT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNIT | ATAI |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2021 |
| Metric | UNIT | ATAI |
|---|---|---|
| Price | $7.22 | $4.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $6.46 | ★ $14.00 |
| AVG Volume (30 Days) | 3.0M | ★ 3.2M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1036.05 | N/A |
| EPS | ★ 8.00 | N/A |
| Revenue | ★ $1,610,627,000.00 | $3,018,000.00 |
| Revenue This Year | $97.87 | $943.83 |
| Revenue Next Year | $59.16 | N/A |
| P/E Ratio | $0.89 | ★ N/A |
| Revenue Growth | 38.94 | ★ 811.78 |
| 52 Week Low | $5.30 | $1.15 |
| 52 Week High | $10.23 | $6.75 |
| Indicator | UNIT | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 62.60 | 51.50 |
| Support Level | $7.02 | $3.88 |
| Resistance Level | $7.63 | $4.33 |
| Average True Range (ATR) | 0.28 | 0.25 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 67.45 | 59.49 |
Uniti is the product of the August 2025 merger of the firm with Windstream, its former primary customer. The combined firm owns a 217,000 route-mile fiber network that primarily serves enterprise customers. This fiber business generates about 20% of consolidated revenue. Uniti also owns phone networks that reach about 4.5 million households, mostly in less-populated markets in the Southeast. Uniti is rapidly upgrading this network to offer fiber-based broadband services. Its fiber network reaches about 1.8 million locations in its service territory. Residential telecom services account for about a third of total revenue. Small business and wholesale services provided over the legacy phone network account for about 20% of revenue.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.